Metraipolis › archive › dc_39a62f3dc03e

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell… — Europe PMC PMID:42734867

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42734867
DOI
10.1186/s43046-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-10-10T02:57:43.842Z
SHA-256 of the archived text
01369013395295429a7a27be0c4772ae984164a12835836117333b8b003d687c
Stable URL of this page
https://metraipolis.com/documento/dc_39a62f3dc03e

How to cite

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell… — Europe PMC PMID:42734867 — Europe PMC (en), https://europepmc.org/article/MED/42734867 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_39a62f3dc03e (Metraipolis archive dc_39a62f3dc03e, sha256 01369013395295429a7a27be0c4772ae984164a12835836117333b8b003d687c)
BibTeX
@misc{dc39a62f3dc03e,
  title = {Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell… — Europe PMC PMID:42734867},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42734867},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_39a62f3dc03e; sha256 01369013395295429a7a27be0c4772ae984164a12835836117333b8b003d687c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42734867. Agents can read the archived copy with the MCP tool read_document.